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A highly sensitive label-free assay for the determination of blood coagulation Factor XIII 
activity is demonstrated through the controlled assembly of peptide-functionalized gold 
nanoparticles (AuNPs). Activated Factor XIII catalyzes the formation of covalent 
crosslinking between peptide chains through ε-(γ-glutamyl)-lysine bonds leading to the 
aggregation of the AuNPs and consequently a red-shift of the localized surface plasmon 
resonance. The selective engineering of nanoscale order over AuNP crosslinking via the 
formation of isopeptide bonds provides a new approach toward the design of nanoassemblies 
with precise control on the molecular level. The colorimetric assay reported here provides 
direct qualitative and quantitative analysis of Factor XIII activity with a limit of detection of 
0.01 U mL−1. 
 
Factor XIII is a key enzyme in the blood coagulation pathway and has attracted significant 
attention due to its clinical importance in hemostasis, angiogenesis, wound healing, and tissue 
repair.1–3 It belongs to the family of transglutaminases, and upon activation by thrombin and 
Ca2+ catalyzes the formation of highly-organized intermolecular crosslinks between glutamine 
and lysine residues on fibrin molecules, forming stable blood clots that prevent excessive 
bleeding from damaged blood vessels. Pathological Factor XIII deficiency is associated with 
severe life-threatening bleeding, impaired wound healing, intracranial hemorrhage, recurrent 
pregnancy losses, and cardiovascular and gastrointestinal disorders.4–8 Over the past decades, 
various detection methods have been developed for the determination of Factor XIII activity, 
including gel electrophoresis,9 enzyme-linked immunosorbent assay (ELISA),10 and 
fluorescence resonance energy transfer (FRET)-based assays.11 In commercially available 
Factor XIII assays, two main detection approaches are used: (i) detection of ammonia 
released during the transglutaminase reaction12,13 or (ii) incorporation of labeled amine 
(fluorescent-, radio-, or biotin-labeled) into a glutamine residue.14–16 The former approach is 
rapid, but it has relatively low sensitivity; the latter approach is time consuming, difficult to 
standardize, and often overestimates the Factor XIII levels.17,18 Hence, despite a significant 
level of development, these techniques still fail to address the great need for specific and 
sensitive assays that allow for the detection of Factor XIII activity at clinically relevant 
concentrations, and Factor XIII deficiency remains the most underdiagnosed bleeding 
disorder.18–20  
The development of state-of-the-art strategies to create bioresponsive nanomaterials has 
opened up new avenues for clinical diagnosis. In particular, gold nanoparticles (AuNPs) show 
great promise as outstanding building blocks for the detection of specific target biomolecules 
due to their unique optical properties that arise from the localized surface plasmon resonance 
(LSPR) phenomenon. LSPR gives rise to a characteristic absorbance peak in the visible 
region of the electromagnetic spectrum that can be tuned by manipulating the morphology 
and/or interparticle separation of the AuNPs.21–25 The versatile surface chemistry available 
for functionalization of AuNPs facilitates the use of specific molecular recognitions to control 
the aggregation state of a suspension of particles, which results in a shift in the absorbance 
peak. This phenomenon allows colorimetric detection of a range of molecular analytes such 
as enzymes,26–28 DNA,29 proteins,30 ions,31 and small molecules.32 
To advance the state-of-the-art of enzyme-responsive nanoparticles and to overcome the 
limitations of current Factor XIII detection techniques, here we utilize AuNPs as an excellent 
sensing platform and develop a label-free detection assay for blood coagulation Factor XIII 
activity based on the controlled aggregation of peptide-functionalized AuNPs (Fig. 1). 
Particles are functionalized with a Factor XIII reactive peptide domain containing glutamine 
or lysine residues, and the activity of the blood coagulation factor results in the formation of 
ε-(γ-glutamyl)-lysine isopeptide bonds, leading to particle aggregation, and therefore a 
significant decrease in interparticle separation distances. Qualitative and quantitative analysis 
can be achieved based on a color change of the AuNP solution and the red-shift of the LSPR, 
respectively, which is dependent on the concentration and activity of Factor XIII. In 
particular in this study, we: (i) surface functionalize AuNPs with custom-designed synthetic 
peptide substrates for Factor XIII; (ii) demonstrate the detection of Factor XIII activity based 
on the crosslinking and aggregation of peptide-functionalized AuNPs; and (iii) investigate the 
specificity and sensitivity of the assay and identify the limit of detection of Factor XIII. 
We designed two peptide substrates, Cys-Ala-Leu-Asn-Asn-Gly-Gln-Gly (CALNNGQG) 
and Cys-Ala-Leu-Asn-Asn-Gly-Lys-Gly (CALNNGKG). The rationale behind the design of 
these peptides is as follows: (i) conjugation of pentapeptide CALNN to the surface of AuNPs 
promotes stability of the particles at physiological salt concentration;33 (ii) cysteine (C) 
residue facilitates the immobilization of the peptides to AuNP surfaces via thiol-gold 
chemistry; and (iii) glutamine (Q) and lysine (K) residues act as substrates for Factor XIII. 
Surface functionalization of 15 nm-diameter spherical AuNPs with CALNNGQG or 
CALNNGKG peptides was assessed using UV-Vis spectrophotometry (Fig. 2a). The stability 
of AuNPs is very sensitive to the external environment of the particles. CALNNGQG 
rendered the particles stable at physiological salt concentration (PBS buffer – 10 mM 
phosphate, 2.7 mM KCl, 137 mM NaCl, pH 7.4), evidenced by a characteristic LSPR peak at 
522 nm (Fig. 2a, red), which is in agreement with previous results on CALNN-functionalized 
AuNPs.33 Under the same physiological conditions, non-functionalized AuNPs aggregated 
instantly due to the charge screening effect and exhibited an absorbance peak at longer 
wavelength (Fig. 2a, black). This difference demonstrates the surface functionalization of the 
AuNPs with CALNNGQG peptide. CALNNGKG-capped AuNPs, on the other hand, caused 
a significant red-shift of 40 nm in the SPR peak (Fig. 2a, orange). This is likely due to the 
strong interaction of amino groups of lysine residues with Au surfaces34 that may alter the 
configuration of CALNN monolayer assembly, a key feature for maintaining the stability of 
AuNPs.33 To obtain a stable suspension of lysine-modified AuNPs, we sought a feasible 
alternative peptide substrate. Poly(L-lysine) (PLL) is a synthetic peptide consisting of a long 
chain of lysine residues and has been used as a coating layer to obtain particles with excellent 
colloidal stability.35,36 As shown in the absorption spectrum, PLL-capped AuNPs remained 
dispersed as indicated by the characteristic LSPR peak at 522 nm (Fig. 2a, blue). The surface 
modification of AuNPs with the peptide substrates was further verified by zeta potential 
measurements (Fig. 2b). Upon adsorption of CALNNGQG or PLL, the zeta potential shifted 
significantly from −24 ± 4 mV for bare AuNPs (black) to 2 ± 8 mV and 19 ± 7 mV for 
CALNNGQG-capped (red) and PLL-capped (blue) AuNPs, respectively. The changes in the 
zeta potential of the AuNPs demonstrated the successful surface functionalization of the 
particles. 
Having characterized the surface functionalization of AuNPs with suitable peptide substrates, 
we tested the enzyme-responsiveness of this system and demonstrated the detection of blood 
coagulation Factor XIII through covalent crosslinking between the peptide chains, leading to 
particle aggregation and changes in interparticle separation distances. A population of 
CALNNGQG- and PLL-capped AuNPs in PBS buffer pH 7.4 was incubated with Factor XIII 
in the presence of thrombin and CaCl2, which are essential components for the activation of 
Factor XIII zymogen. To increase the sensitivity of the enzyme-responsive assay, the 
concentrations of the assay components were optimized and determined to be 20 U mL−1 
thrombin and 1 mM CaCl2 (Fig. S1, ESI†). This produced maximal and complete activation 
of Factor XIII to obtain the highest LSPR peak shift for the AuNP aggregation-based assay. 
Fig. 3a shows the UV-Vis absorption spectra of the AuNP mixtures in the absence or 
presence of Factor XIII. Upon introduction of 0.5 U mL−1 Factor XIII, the enzyme catalyzed 
the formation of ε-(γ-glutamyl)-lysine isopeptide bonds between glutamine residues of 
CALNNGQG peptide and lysine residues of PLL, with particle crosslinking giving a 
significant red-shift of the LSPR peak, from 522 to 559 nm. This shift could be monitored in 
real time and the kinetics of the aggregation process showed that a maximum LSPR peak 
shift was obtained over an incubation time of 120 min (Fig. 3b). When the AuNP mixtures 
were exposed to only one of the assay components (i.e., Factor XIII, thrombin, or CaCl2 
alone), no shift of the LSPR peak was observed (Fig. 3b). This observation confirmed that the 
aggregation of the particles is dependent on the activity of Factor XIII rather than simply the 
presence of the assay components. Corresponding transmission electron microscopy (TEM) 
images and photographs of the peptide-functionalized AuNP solutions before and after 
incubation with Factor XIII are shown in panels (i) and (ii) of Fig. 3c and d, respectively. The 
TEM images confirmed the state of aggregation of the AuNPs, which can be detected by the 
naked eye through a red-to-blue color change. Thus, the correlation between the aggregation 
state of the AuNPs and their optical properties facilitates qualitative detection of Factor XIII 
activity. 
 
To the best of our knowledge, this is the first report describing the controlled crosslinking of 
AuNPs through the formation of ε-(γ-glutamyl)-lysine isopeptide bonds, allowing precise 
spatial control of materials at the nanoscale. This selective engineering of nanoscale order 
advances the state-of-the-art of enzyme-responsive molecular recognition for self-assembly 
of AuNPs, which not only plays a crucial role toward the development of new tools for 
diagnostics, but also serves as a promising route for the design of molecular-scale devices. 
To further confirm that the crosslinking of the peptide chains on AuNPs and the particle 
aggregation is specific to Factor XIII activity, control experiments were performed with 
potential interfering enzymes such as lysozyme and phospholipase. As shown in Fig. 3e, the 
signal intensities of peptide–AuNP mixtures incubated with lysozyme or phospholipase are 
negligible, and only in the presence of Factor XIII is a significant LSPR induced. Similarly, 
when glutamine or lysine residues were replaced (i.e., Factor XIII was added to a population 
of CALNNGQG-capped AuNPs alone, PLL-capped AuNPs alone, or a mixture of CALNN- 
and PLL-capped AuNPs), crosslinking of the particles cannot be formed (Fig. 3e). 
Fig. 3f summarizes the shift of the LSPR peak upon introduction of various concentrations of 
Factor XIII (0.5 U mL−1 down to 0.01 U mL−1) into a population of CALNNGQG- and PLL-
capped AuNPs in the presence of 20 U mL−1 thrombin, 1 mM CaCl2, and 1 mg mL−1 human 
serum albumin (HSA). The addition of HSA, which is the most abundant protein in serum, to 
the AuNP mixture did not induce particle aggregation. The limit of detection of Factor XIII in 
this AuNP assay is derived from the calibration curve (Fig. 3g), and is defined as the lowest 
concentration of Factor XIII that yields a signal three times higher than the standard deviation 
of the blank.37 The limit of detection of Factor XIII activity based on the aggregation of the 
peptide-functionalized AuNPs is determined to be 0.01 U mL−1. This represents a clinically 
relevant level of Factor XIII ( 0.05 U mL−1) that is not readily detectable by the state-of-the 
art diagnosis18 and the present assay shows great promise for the development of diagnostic 
tools for the detection of Factor XIII deficiency. The high sensitivity of this assay is 
attributed to the specific recognition and subsequent crosslinking of peptide substrates by 
activated Factor XIII, with the unique plasmonic properties of the AuNP leading to highly 
specific and sensitive detection of target biomolecules. 
We have demonstrated a highly sensitive label-free detection approach for Factor XIII 
activity based on controlled aggregation of peptide-functionalized AuNPs, which provides 
qualitative and quantitative analysis with a limit of detection of 0.01 U mL−1. The current 
assay not only presents new and exciting opportunities en route to the development of a 
diagnostic test for Factor XIII deficiency, but also demonstrates precise nanoscale control 
over AuNP crosslinking via the formation of ε-(γ-glutamyl)-lysine isopeptide bonds. This 
further advances the state-of-the-art of enzyme-responsive molecular-mediated bridging for 
AuNP self-assembly and serves as a promising route for the design of nanoassemblies with 
precise control on the molecular level. We anticipate the simplicity of the colorimetric assay 
coupled with high specificity and sensitivity will be valuable in prompt identification and 
early intervention for controlling potential life threatening complications. 
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Fig. 1 Schematic illustration of label-free detection of blood coagulation Factor XIII activity based on controlled assembly of peptide-
functionalized gold nanoparticles (AuNPs). Particles are functionalized with peptides containing glutamine (Gln) or lysine (Lys) residues and 
the activity of Factor XIII results in the formation of covalent crosslinking between the peptide chains through ε-(γ-glutamyl)-lysine bonds, 
leading to particle aggregation. This highly sensitive assay allows qualitative (color change of AuNP solution) and quantitative (red-shift of the 
localized surface plasmon resonance) analysis that is dependent on the concentration and activity of Factor XIII. 
 
 
  
  
Fig. 2 Peptide-functionalized AuNPs at physiological conditions (PBS buffer pH 7.4). (a) UV-Vis absorption spectra of bare AuNPs (black), 
CALNNGQG-capped AuNPs (red), CALNNGKG-capped AuNPs (orange), and PLL-capped AuNPs (blue). The surface modification of 
AuNPs with CALNNGQG peptide and PLL yielded particles with excellent colloidal stability at physiological salt concentrations. (b) Zeta 
potential measurements of bare AuNPs (black), CALNNGQG-capped AuNPs (red), and PLL-capped AuNPs (blue) verified the surface 
functionalization of the particles. 
 
 
  
  
Fig. 3 Detection of blood coagulation Factor XIII activity based on controlled assembly of 
peptide-functionalized AuNPs. (a) UV-Vis absorption spectra of peptide-functionalized 
AuNPs before (red) and after (blue) exposure to Factor XIII in the presence of 20 U mL−1 
thrombin and 1 mM CaCl2. (b) Kinetics of the AuNP LSPR peak shifts induced by Factor 
XIII-mediated catalysis. (c) Transmission electron microscopy images and (d) photographs 
of the AuNP solutions before (i) and after (ii) exposure to Factor XIII. (e) LSPR peak shift 
of the AuNP solution in the presence of other enzymes or in the absence of peptide 
substrates, demonstrating the specificity of the AuNP-based assay solely mediated by Factor 
XIII activity. (f) UV-Vis absorption spectra of peptide-functionalized AuNPs after exposure 
to various concentrations of Factor XIII (0.01 U mL−1 to 0.5 U mL−1) in the presence of 20 U 
mL−1 thrombin, 1 mM CaCl2, and 1 mg mL−1 human serum albumin. (g) Red-shift of the 
LSPR peak as a function of concentration of Factor XIII (R2 = 0.988), demonstrating the 
sensitivity of the AuNP-based assay for the detection of Factor XIII activity. 
 
